Clinical Trial Update: Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update exploring trilaciclib as a bone marrow protective agent during postoperative concurrent chemoradiation for locally advanced head a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• trilaciclib (trilaciclib)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING